| Literature DB >> 20411076 |
Donald M Dawes1, Jeffrey D Ho, Robert F Reardon, James D Sweeney, James R Miner.
Abstract
OBJECTIVES: Law enforcement and military personnel use electronic control devices to control non-compliant and actively resistive subjects. The TASER((R)) Shockwave is a new electronic control device designed specifically as an area denial device capable of delivering multiple simultaneous discharges. This is the first study to examine the effects of multiple simultaneous device discharges in humans.Entities:
Year: 2010 PMID: 20411076 PMCID: PMC2850854
Source DB: PubMed Journal: West J Emerg Med ISSN: 1936-900X
Demographics
| 1 | 3 | C-A | 48 | M | 22.0 | 28.0 | none | none |
| 2 | 3 | C-A | 32 | M | 25.1 | 30.5 | none | none |
| 3 | 3 | C-A | 22 | M | 35.0 | 36.8 | none | none |
| 4 | 2 | thighs | 24 | F | 36.0 | 27.2 | depression | paroxetine |
| 5 | 2 | thighs | 27 | F | 35.1 | 28.9 | orthopedic surgery | OCP |
| 6 | 3 | C-A | 26 | M | 34.1 | 40.5 | orthopedic surgery | none |
| 7 | 2 | back | 57 | M | 14.0 | 21.5 | orthopedic surgery | none |
| 8 | 2 | back | 34 | M | 21.6 | 27.2 | hernia repair | none |
| 9 | 2 | back | 34 | M | 25.8 | 18.8 | allergies | loratadine |
| 10 | 2 | chest | 38 | M | 27.5 | 31.2 | orthopedic surgery, GERD | esomeprazole, hydrocodone |
| 11 | 2 | chest | 25 | F | 39.6 | 34.2 | orthopedic surgery | none |
| 12 | 2 | chest | 21 | M | 21.7 | 29.5 | orthopedic surgery | none |
| 13 | 3 | C-A | 39 | M | 16.8 | 24.4 | vasectomy | none |
| 14 | 3 | C-A | 19 | M | 17.0 | 23.1 | spontaneous pneumothorax, asthma | albuterol |
| 15 | 3 | C-A | 37 | M | 22.7 | 27.8 | orthopedic surgery | amoxicillin |
| 16 | 3 | C-A | 39 | M | 18.5 | 24.3 | hypothyroidism | levothyroxine |
BMI, body mass index; PMH, past medical history; C-A,chest to abdomen; M, male; F, female; OCP, oral contraceptive pills; GERD, gastroesophageal reflux disease;
Blood results
| Two Probe Pairs | ||||||||
| Lactate(median, range) mmol/L | 1.05, 0.66–2.88 | 0.44 | 3.49, 1.41–4.49 | 0.03 | 0.06 | 1.34, 0.86–2.30 | 0.75 | 0.12 |
| pH(median, range) | 7.35, 7.29–7.40 | 0.49 | 7.33, 7.27–7.38 | 0.24 | 0.008 | 7.35, 7.33–7.40 | 0.18 | 0.999 |
| K(median, range) mmol/L | 4.0, 3.7–4.3 | 0.19 | 4.0, 3.7–4.3 | 0.865 | 0.09 | 4.15, 4.0–4.4 | 0.02 | 0.08 |
| Total creatine kinase (median, range) ng/mL | 130, 39–1956 | 0.35 | 137, 36–1940 | 0.15 | 0.42 | 508, 41–902 | 0.34 | 0.20 |
| Troponin (median, range) ng/mL | 0.0, 0.0– 0.02 | 0.0, 0–0.02 | 0, 0–0.01 | |||||
| Three Probe Pairs | ||||||||
| Lactate (median, range) mmol/L | 1.81, 0.64–2.24 | 2.74, 0.95–3.78 | 0.09 | 1.72, 1.39–2.15 | 0.35 | |||
| pH(median, range) | 7.36, 7.30–7.46 | 7.38, 7.30–7.41 | 0.61 | 7.36, 7.33–7.39 | 0.35 | |||
| K(median, range) mmol/L | 3.85, 3.4–4.5 | 3.6, 3.0–4.3 | 0.397 | 3.95, 3.8–4.7 | 0.02 | |||
| Total creatine kinase (median, range) ng/mL | 173, 130–392 | 173, 129–380 | 0.06 | 1016, 158–2482 | 0.03 | |||
| Troponin (median, range) ng/mL | 0.0, 0.0– 0.02 | 0.0, 0.0– 0.02 | 0.0, 0.0–0.01 | |||||
Breathing results
| Two Probe Pairs | ||||||||
|---|---|---|---|---|---|---|---|---|
| RR – (median, range) Breaths per minute | 13.5, 10–16 | 0.5 | 12, 0–71 | 0.6 | 0.24 | 17.5, 13–22 | 0.01 | 0.33 |
| TV (median, range) Liters (L) | 0.775, 0.35–1.05 | 0.05 | 0.71, 0.40–1.49 | 0.86 | 0.05 | 0.98, 0.53–1.11 | 0.012 | 0.25 |
| MV (median, range) L/minute | 15.6, 11.6–18.2 | 0.71 | 10.8, 6.4–28.5 | 0.23 | 0.57 | 15.6, 11.6–18.2 | 0.01 | 0.71 |
| Three Probe Pairs | ||||||||
| RR – (median, range) Breaths per minute | 13.0, 8–21 | 8, 0–45 | 0.16 | 15.5, 12–19 | 0.08 | |||
| TV (median, range) Liters (L) | 0.955, 0.44–1.92 | 1.9, 0.44–3.04 | 0.116 | 1.075, 0.69–1.39 | 0.674 | |||
| MV (median, range) L/minute | 15.1, 12.6–21.8 | 16.6, 8.9–43.1 | 0.24 | 15.1, 12.6–21.8 | 0.01 | |||
RR, respiratory rate; TV, tidal volume; MV, minute ventilation.
Blinded electrocardiogram interpretations
| 1 | NSR at 86 | NSR at 74 | none |
| 2 | NSR at 95 | NSR at 74 | Rate decreased by 21 |
| 3 | NSR at 79 | NSR at 67 | Rate decreased by 20 |
| 4 | NSR at 90 | NSR | none |
| 5 | NSR at 85 | NSR at 88 | none |
| 6 | NSR at 98 | NSR at 79 | Rate decreased by 19 |
| 7 | NSR at 65, LVH, LAE | Sinus bradycardia at 55, LVH, LAE | Rate decreased by 10 |
| 8 | NSR at 81 | Sinus rhythm at 68 | Sinus node exit block and sinus arrhythmia |
| 9 | NSR at 75, non-specific inferior ST abnormality | NSR at 74, non-specific inferior ST abnormality | none |
| 10 | NSR at 74 | NSR at 87 | Non-specific inferior T wave change, QT interval increased by 50 ms from 394ms to 443ms |
| 11 | NSR at 95 | NSR at 94 | none |
| 12 | NSR at 80, LVH | NSR at 83, LVH | none |
| 13 | NSR at 85 | NSR at 64 | Rate decreased by 21 |
| 14 | Sinus tachycardia at 100, RSR’ | Sinus tachycardia at 102, RSR’ | none |
| 15 | NSR 88 | NSR 92 | none |
| 16 | NSR 71 | NSR 67 | none |
ECG, electrocardiogram; NSR, normal sinus rhythm; LVH, left ventricular hypertrophy; LAE, left atrial enlargement.
Figure 1.Electrocardiograms (ECGs) from Subject 10 showing non-specific inferior T wave changes (before and after ECGs).
M-mode echocardiography results
| 1 | 78 | 111 | 73 | Sinus |
| 2 | 71 | 113 | 63 | Sinus |
| 3 | 83 | 118 | 59 | Sinus |
| 4 | 98 | 143 | 82 | Sinus |
| 5 | 78 | 79 | 78 | Indeterminate |
| 6 | 87 | 158 | 77 | Indeterminate |
Figure 2.Types of exposures
Vitals signs before and after discharge
| 1 | 143/79, 81 | 198/93, 84 |
| 2 | 142/79, 89 | 133/80, 104 |
| 3 | 134/78, 82 | 137/77, 60 |
| 4 | 131/85, 105 | 157/84, 90 |
| 5 | 141/93, 90 | 141/79, 81 |
| 6 | 139/85, 101 | 151/70, 85 |
| 7 | 131/78, 92 | 154/70, 88 |
| 8 | 116/76, 70 | 155/66, 69 |
| 9 | 143/61, 87 | 131/76, 75 |
| 10 | 158/83, 69 | 133/75, 79 |
| 11 | 122/83, 98 | 154/83, 97 |
| 12 | 159/80, 83 | 147/79, 70 |
| 13 | 130/73, 76 | 117/70, 75 |
| 14 | 159/76, 90 | 126/85, 120 |
| 15 | 155/85, 88 | 157/80, 91 |
| 16 | 122/85, not recorded | 157/71, not recorded |